ALK rearrangements have generally been reported to be mutually exclusive with other driver alterations in NSCLC such as EGFR and KRAS mutations, although few studies have shown that they can coexist [30,31,32]. This evidence concerns the gene ALK and non-small cell lung carcinoma.